Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer’s disease models: a systematic review and meta-analysis of preclinical studies

Alzheimer's disease

Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465 · see citing works

Alzheimer’s disease

Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569 · see citing works

Inflammation and Alzheimer’s disease

Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514 · see citing works

SYRCLE’s risk of bias tool for animal studies

Hooijmans, C. R., Rovers, M. M., de Vries, R. B., Leenaars, M., Ritskes-Hoitinga, M., & Langendam, M. W. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-43 · Cited by 4,415 · see citing works

Coupling of Stress in the ER to Activation of JNK Protein Kinases by Transmembrane Protein Kinase IRE1

Urano, F., Wang, X.-Z., Bertolotti, A., Zhang, Y., Chung, P., Harding, H. P., & Ron, D. (2000) · Science · doi:10.1126/science.287.5453.664 · Cited by 2,997 · see citing works

Alzheimer disease

Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606 · see citing works

Neurodegenerative Tauopathies

Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · see citing works

Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline

Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · see citing works

Glucagon-like peptide 1 (GLP-1)

Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · see citing works

Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction

Nation, D. A., Sweeney, M. D., Montagne, A., Sagare, A. P., D’Orazio, L. M., Pachicano, M., Sepehrband, F., Nelson, A. R., Buennagel, D. P., Harrington, M. G., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0297-y · Cited by 1,728 · see citing works

Neuroinflammation in Alzheimer's disease: current evidence and future directions

Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726 · see citing works

Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes?

Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · see citing works

Pharmacology, physiology, and mechanisms of incretin hormone action.

Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · see citing works

The role of estrogens in control of energy balance and glucose homeostasis

Mauvais-Jarvis, F., Clegg, D. J., & Hevener, A. L. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1055 · Cited by 1,329 · see citing works

Alzheimer’s disease: Clinical trials and drug development

Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217 · see citing works

The Glucagon-Like Peptides

Kieffer, T. J., & Habener, J. F. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,056 · see citing works

Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment

Scheff, S. W., Price, D. A., Schmitt, F. A., & Mufson, E. J. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.012 · Cited by 1,017 · see citing works

Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology

Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986 · see citing works

Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia

Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · see citing works

Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog

Hubbard, S. R. (1997) · The EMBO Journal · doi:10.1093/emboj/16.18.5572 · Cited by 954 · see citing works

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · see citing works

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers

Bomfim, T. R., Forny‐Germano, L., Sathler, L. B., Brito‐Moreira, J., Houzel, J., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 830 · see citing works

Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease

Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820 · cited 1× · see citing works

Alzheimer's disease: experimental models and reality

Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810 · see citing works

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · see citing works

Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: Link to brain reductions in acetylcholine

Rivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723 · see citing works

Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model

Du, H., Guo, L., Yan, S., Sosunov, A. A., McKhann, G. M., & ShiDu Yan, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006586107 · Cited by 704 · see citing works

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698 · see citing works

Insulin Action in Brain Regulates Systemic Metabolism and Brain Function

Kleinridders, A., Ferris, H. A., Cai, W., & Kahn, C. R. (2014) · Diabetes · doi:10.2337/db14-0568 · Cited by 688 · see citing works

Animal models of Alzheimer's disease and frontotemporal dementia

Götz, J., & Ittner, L. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2420 · Cited by 676 · see citing works

APPSW Transgenic Mice Develop Age-related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1

IRIZARRY, M. C., MCNAMARA, M., FEDORCHAK, K., HSIAO, K., & HYMAN, B. T. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199709000-00002 · Cited by 649 · see citing works

Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons

Stranahan, A. M., Arumugam, T. V., Cutler, R. G., Lee, K. M., Egan, J. M., & Mattson, M. P. (2008) · Nature Neuroscience · doi:10.1038/nn2055 · Cited by 610 · see citing works

Brain Glucose Hypometabolism and Oxidative Stress in Preclinical Alzheimer's Disease

Mosconi, L., Pupi, A., & de Leon, M. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.007 · Cited by 599 · see citing works

Advanced Glycation End Products (AGE) and Diabetes: Cause, Effect, or Both?

Vlassara, H., & Uribarri, J. (2014) · Current Diabetes Reports · doi:10.1007/s11892-013-0453-1 · Cited by 594 · see citing works

Microglia-Astrocyte Crosstalk: An Intimate Molecular Conversation

Jha, M. K., Jo, M., Kim, J.-H., & Suk, K. (2019) · The Neuroscientist · doi:10.1177/1073858418783959 · Cited by 579 · see citing works

Elevated circulating tumor necrosis factor levels in Alzheimer's disease

Fillit, H. M., Ding, W., Buée, L., Kalman, J., Altstiel, L. D., LAWLOR, B. A., & Wolf-Klein, G. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90490-k · Cited by 513 · see citing works

Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease

Simpson, I. A., Chundu, K. R., Davies‐Hill, T., Honer, W. G., & Davies, P. (1994) · Annals of Neurology · doi:10.1002/ana.410350507 · Cited by 490 · see citing works

In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480 · see citing works

The importance of tau phosphorylation for neurodegenerative diseases

Noble, W., Hanger, D. P., Miller, C. C. J., & Lovestone, S. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00083 · Cited by 475 · see citing works

Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer’s disease

Lester-Coll, N., Rivera, E. J., Soscia, S. J., Doiron, K., Wands, J. R., & de la Monte, S. M. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9102 · Cited by 467 · see citing works

Involvement of Endoplasmic Reticulum Stress in Insulin Resistance and Diabetes

Nakatani, Y., Kaneto, H., Kawamori, D., Yoshiuchi, K., Hatazaki, M., Matsuoka, T., Ozawa, K., Ogawa, S., Hori, M., Yamasaki, Y., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411860200 · Cited by 462 · see citing works

Why does Brain Metabolism not Favor Burning of Fatty Acids to Provide Energy? - Reflections on Disadvantages of the Use of Free Fatty Acids as Fuel for Brain

Schönfeld, P., & Reiser, G. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.128 · Cited by 457 · see citing works

Evidence for brain glucose dysregulation in Alzheimer’s disease

An, Y., Varma, V., Varma, S., Casanova, R., Dammer, E., Pletnikova, O., Chia, C. W., Egan, J. M., Ferrucci, L., Troncoso, J., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.011 · Cited by 454 · see citing works

Why Women Have More Alzheimer's Disease Than Men: Gender and Mitochondrial Toxicity of Amyloid-β Peptide

Viña, J., & Lloret, A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100501 · Cited by 447 · see citing works

Synaptic Impairment in Alzheimer’s Disease: A Dysregulated Symphony

Forner, S., Baglietto-Vargas, D., Martini, A. C., Trujillo-Estrada, L., & LaFerla, F. M. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.04.002 · Cited by 430 · see citing works

Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms

Sastre, M., Klockgether, T., & Heneka, M. T. (2006) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.014 · Cited by 426 · see citing works

Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo

Chiu, S.-L., Chen, C.-M., & Cline, H. T. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.014 · Cited by 425 · see citing works

Obesity-induced endoplasmic reticulum stress causes chronic inflammation in adipose tissue

Kawasaki, N., Asada, R., Saito, A., Kanemoto, S., & Imaizumi, K. (2012) · Scientific Reports · doi:10.1038/srep00799 · Cited by 404 · see citing works

Insulin and Insulin Resistance in Alzheimer’s Disease

Sędzikowska, A., & Szablewski, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189987 · Cited by 404 · see citing works

Research priorities to reduce the global burden of dementia by 2025

Shah, H., Albanese, E., Duggan, C. D., Rudan, I., Langa, K. M., Carrillo, M. C., Chan, K. Y., Joanette, Y., Prince, M. J., Rossor, M. N., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30235-6 · Cited by 379 · see citing works

Protein Adducts Generated from Products of Lipid Oxidation: Focus on HNE and ONE

Sayre, L. M., Lin, D., Yuan, Q., Zhu, X., & Tang, X. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600959508 · Cited by 364 · see citing works

Synaptic basis of Alzheimer’s disease: Focus on synaptic amyloid beta, P-tau and mitochondria

John, A., & Reddy, P. H. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101208 · Cited by 359 · see citing works

Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease

McClean, P. L., & Hölscher, C. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.005 · Cited by 359 · see citing works

Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease

Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345 · see citing works

Type 3 Diabetes and Its Role Implications in Alzheimer’s Disease

Nguyen, T. T., Ta, Q., Nguyen, T. K. O., Nguyen, T., & Vo, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093165 · Cited by 338 · see citing works

Oxidative toxicity in diabetes and Alzheimer’s disease: mechanisms behind ROS/ RNS generation

Ahmad, W., Ijaz, B., Shabbiri, K., Ahmed, F., & Rehman, S. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0379-z · Cited by 334 · see citing works

Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients.

Strauss, S., Bauer, J., Ganter, U., Jonas, U., Berger, T., & Volk, B. (1992) · PubMed · Cited by 331 · see citing works

Preventing dementia by preventing stroke: The Berlin Manifesto

Hachinski, V., Einhäupl, K. M., Ganten, D., Alladi, S., Brayne, C., Stephan, B. C. M., Sweeney, M. D., Zloković, B. V., Iturria‐Medina, Y., Iadecola, C., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.06.001 · Cited by 314 · see citing works

Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?

Bassil, F., Fernagut, P., Bézard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 313 · see citing works

Calcium Hypothesis of Alzheimer’s disease and brain aging: a framework for integrating new evidence into a comprehensive theory of pathogenesis

Alzheimer's Association Calcium Hypothesis Workgroup, & Khachaturian, Z. S. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.12.006 · Cited by 311 · see citing works

The expression of GLP‐1 receptor mRNA and protein allows the effect of GLP‐1 on glucose metabolism in the human hypothalamus and brainstem

Álvarez, E., Martínez, M. D., Roncero, I., Chowen, J. A., Cuartero, B. G., Gispert, J. D., Sanz, C., Vázquez, P., Maldonado, A., Cáceres, J. D., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02914.x · Cited by 307 · see citing works

Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review

Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306 · see citing works

GLP-1 receptor agonists: an updated review of head-to-head clinical studies

Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289 · see citing works

Mouse models of Alzheimer’s disease

Esquerda-Canals, G., Montoliu-Gaya, L., Güell-Bosch, J., & Villegas, S. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170045 · Cited by 288 · see citing works

A Non-transgenic Mouse Model (icv-STZ Mouse) of Alzheimer’s Disease: Similarities to and Differences from the Transgenic Model (3xTg-AD Mouse)

Chen, Y., Liang, Z., Blanchard, J., Dai, C., Sun, S., Lee, M. H., Grundke, I., Iqbal, K., Liu, F., & Gong, C. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8375-5 · Cited by 286 · see citing works

Oxidative Stress in Diabetes and Alzheimer's Disease

Reddy, V. P., Zhu, X., Perry, G. L., & Smith, M. A. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1013 · Cited by 283 · see citing works

Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease

Abbas, T. F., Faivre, É., & Hölscher, C. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.035 · Cited by 282 · see citing works

What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer’s disease, about the therapeutic strategies in Alzheimer’s research

Šalković‐Petrišić, M., Knezović, A., Hoyer, S., & Riederer, P. F. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0877-9 · Cited by 272 · see citing works

Neuroprotective and neurotrophic actions of glucagon‐like peptide‐1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders

Salcedo, I., Tweedie, D., Li, Y., & Greig, N. H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01971.x · Cited by 263 · see citing works

The Biphasic Relationship between Regional Brain Senile Plaque and Neurofibrillary Tangle Distributions: Modification by Age, Sex, and <i>APOE</i> Polymorphism

CORDER, E. H., GHEBREMEDHIN, E., TAYLOR, M. G., THAL, D. R., OHM, T. G., & BRAAK, H. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1297.005 · Cited by 254 · see citing works

Apolipoprotein E, gender, and Alzheimer’s disease: an overlooked, but potent and promising interaction

Ungar, L., Altmann, A., & Greicius, M. D. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9272-x · Cited by 246 · see citing works

The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases

Wu, M., Zhang, M., Yin, X., Chen, K., Hu, Z., Zhou, Q., Cao, X., Chen, Z., & Liu, D. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00270-1 · Cited by 241 · see citing works

Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system

Hamilton, A., & Hölscher, C. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832fbf14 · Cited by 227 · see citing works

Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases

Reddy, P. H., & Reddy, T. P. (2011) · Current Alzheimer Research · doi:10.2174/156720511795745401 · Cited by 227 · see citing works

Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type?

Hoyer, S., Oesterreich, K., & Wagner, O. (1988) · Journal of Neurology · doi:10.1007/bf00314304 · Cited by 224 · see citing works

Rodent models for Alzheimer’s disease drug discovery

Puzzo, D., Gulisano, W., Palmeri, A., & Arancio, O. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1041913 · Cited by 222 · see citing works

Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases

Grieco, M., Giorgi, A., Gentile, M. C., d’Erme, M., Morano, S., Maras, B., & Filardi, T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01112 · Cited by 218 · cited 3× · see citing works

Insulin receptor signaling in long-term memory consolidation following spatial learningPreprint

Dou, J., Chen, M., Dufour, F., Alkon, D. L., & Zhao, W. (2005) · Learning & Memory · doi:10.1101/lm.88005 · Cited by 217 · see citing works

Novel GLP‐1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

Hamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210 · see citing works

Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase

Malm-Erjefält, M., Bjørnsdottir, I., Vanggaard, J., Helleberg, H., Larsen, U. S., Oosterhuis, B., van Lier, J. J., Zdravkovic, M., & Olsen, A. K. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034066 · Cited by 201 · see citing works

Changes in insulin and insulin signaling in Alzheimer’s disease: cause or consequence?

Stanley, M., Macauley, S. L., & Holtzman, D. M. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20160493 · Cited by 199 · see citing works

Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease

Kurochkin, I. V., Guarnera, E., & Berezovsky, I. N. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.10.008 · Cited by 185 · see citing works

Brain insulin resistance: role in neurodegenerative disease and potential for targeting

Hölscher, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1738383 · Cited by 180 · see citing works

The presenilin-1 ΔE9 mutation results in reduced γ-secretase activity, but not total loss of PS1 function, in isogenic human stem cells

Woodruff, G., Young, J. E., Martinez, F. J., Buen, F., Gore, A., Kinaga, J., Li, Z., Yuan, S. H., Zhang, K., & Goldstein, L. S. B. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.018 · Cited by 177 · see citing works

Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease

Bakota, L., & Brandt, R. (2016) · Drugs · doi:10.1007/s40265-015-0529-0 · Cited by 170 · see citing works

Sex Differences in Alzheimer’s Disease: Insights From the Multiomics Landscape

Guo, L., Zhong, M. B., Zhang, L., Zhang, B., & Cai, D. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.02.968 · Cited by 164 · see citing works

White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease

Klosinski, L. P., Yao, J., Yin, F., Fonteh, A. N., Harrington, M. G., Christensen, T. A., Trushina, E. V., & Brinton, R. D. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.11.002 · Cited by 164 · see citing works

A Pilot Study of Exenatide Actions in Alzheimer’s Disease

Mullins, R. J., Mustapić, M., Chia, C. W., Carlson, O. D., Gulyani, S., Tran, J., Li, Y., Mattson, M. P., Resnick, S. M., Egan, J. M., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190913155950 · Cited by 160 · see citing works

The Insulin Receptor: Both a Prototypical and Atypical Receptor Tyrosine KinasePreprint

Hubbard, S. R. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008946 · Cited by 155 · see citing works

Diabetes drugs and neurological disorders: new views and therapeutic possibilities

Patrone, C., Eriksson, O., & Lindholm, D. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70125-6 · Cited by 154 · see citing works

Inflammation-Dependent Cerebral Deposition of Serum Amyloid A Protein in a Mouse Model of Amyloidosis

Guo, J.-T., Yu, J., Grass, D., de Beer, F. C., & Kindy, M. S. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-14-05900.2002 · Cited by 153 · see citing works

Chronic treatment with tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative–nitrosative stress in rats

Tiwari, V., Kuhad, A., Bishnoi, M., & Chopra, K. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.05.009 · Cited by 153 · see citing works

Neuroprotective and anti‐apoptotic effects of liraglutide on <scp>SH</scp>‐<scp>SY</scp>5Y cells exposed to methylglyoxal stress

Sharma, M. K., Jalewa, J., & Hölscher, C. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12469 · Cited by 151 · see citing works

Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats

Duelli, R., Schröck, H., Kuschinsky, W., & Hoyer, S. (1994) · International Journal of Developmental Neuroscience · doi:10.1016/0736-5748(94)90053-1 · Cited by 150 · see citing works

Enhancing the GLP‐1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells

Li, Y., Tweedie, D., Mattson, M. P., Holloway, H. W., & Greig, N. H. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06731.x · Cited by 149 · see citing works

Okadaic acid induced neurotoxicity: An emerging tool to study Alzheimer's disease pathology

Kamat, P. K., Rai, S., & Nath, C. (2013) · NeuroToxicology · doi:10.1016/j.neuro.2013.05.002 · Cited by 149 · see citing works

Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases

Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148 · see citing works

Local action of the diabetogenic drug, streptozotocin, on glucose and energy metabolism in rat brain cortex

Nitsch, R. M., & Hoyer, S. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90260-z · Cited by 146 · see citing works

Alzheimer's disease: Effects of β-amyloid on mitochondria

Tillement, L., Lecanu, L., & Papadopoulos, V. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.08.009 · Cited by 145 · see citing works

Diabetes drugs in the fight against Alzheimer's disease

Boccardi, V., Murasecco, I., & Mecocci, P. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100936 · Cited by 142 · see citing works

Gene Dosage Dependent Aggravation of the Neurological Phenotype in the 5XFAD Mouse Model of Alzheimer’s Disease

Richard, B. C., Kurdakova, A., Baches, S., Bayer, T. A., Weggen, S., & Wirths, O. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-143120 · Cited by 142 · see citing works

Geniposide Ameliorates Learning Memory Deficits, Reduces Tau Phosphorylation and Decreases Apoptosis via GSK 3β Pathway in Streptozotocin‐Induced A lzheimer Rat Model

Gao, C., Liu, Y., Jiang, Y., Ding, J., & Li, L. (2013) · Brain Pathology · doi:10.1111/bpa.12116 · Cited by 141 · see citing works

Brain Insulin Resistance in Alzheimer's Disease and its Potential Treatment with GLP-1 Analogs

Talbot, K. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.73 · Cited by 139 · see citing works

Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats

Han, W.-N., Hölscher, C., Yuan, L., Yang, W., Wang, X., Wu, M., & Qi, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.009 · Cited by 138 · see citing works

Differential effects of glycation on protein aggregation and amyloid formation

Iannuzzi, C., Irace, G., & Sirangelo, I. (2014) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2014.00009 · Cited by 137 · see citing works

Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment

Chakrabarti, S., Kumar Khemka, V., Banerjee, A., Chatterjee, G., Ganguly, A., & Biswas, A. (2015) · Aging and disease · doi:10.14336/ad.2014.002 · Cited by 134 · see citing works

Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model

Qi, L., Ke, L., Liu, X., Liao, L., Ke, S., Liu, X., Wang, Y., Lin, X., Zhou, Y., Wu, L., et al. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.04.052 · Cited by 128 · see citing works

PI3 kinase signaling is involved in Aβ-induced memory loss in Drosophila

Chiang, H., Wang, L., Xie, Z., Yau, A., & Zhong, Y. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909314107 · Cited by 127 · see citing works

Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice

McClean, P. L., Jalewa, J., & Hölscher, C. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.024 · Cited by 125 · see citing works

Metabolism and pharmacokinetics of genipin and geniposide in rats

Hou, Y., Tsai, S. Y., Lai, P. Y., et al. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2008.04.033 · Cited by 120 · see citing works

Modeling Sporadic Alzheimer's Disease: The Insulin Resistant Brain State Generates Multiple Long-Term Morphobiological Abnormalities Including Hyperphosphorylated Tau Protein and Amyloid-β

Šalković‐Petrišić, M., Barilar, J. O., Grünblatt, E., Riederer, P. F., & Hoyer, S. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1184 · Cited by 119 · see citing works

Mitochondrial Abnormalities in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer's Disease

Correia, S. C., Santos, R. X., Santos, M. S., Casadesús, G., LaManna, J. C., Perry, G. L., Smith, M. A., & Moreira, P. I. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310040006 · Cited by 116 · see citing works

Molecular and Cellular Mechanism of Okadaic Acid (OKA)-Induced Neurotoxicity: A Novel Tool for Alzheimer’s Disease Therapeutic Application

Kamat, P. K., Rai, S., Swarnkar, S., Shukla, R., & Nath, C. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8699-4 · Cited by 112 · see citing works

Gantenerumab: An anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Bateman, R. J., Cummings, J., Schobel, S., Salloway, S., Vellas, B., Boada, M., Black, S. E., Blennow, K., Fontoura, P., Klein, G., et al. (2022) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-022-01110-8 · Cited by 109 · see citing works

Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats

Cai, H.-Y., Hölscher, C., Yue, X.-H., Zhang, S., Wang, X.-H., Qiao, F., Yang, W., & Qi, J. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.02.022 · Cited by 106 · see citing works

Desensitization of brain insulin receptor Effect on glucose/energy and related metabolism

Hoyer, S., Müller, D., & Plaschke, K. (1994) · Springer eBooks · doi:10.1007/978-3-7091-9350-1_20 · Cited by 104 · see citing works

c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo

Sclip, A., Tozzi, A., Abaza, A., Cardinetti, D., Colombo, I., Calabresi, P., Salmona, M., Welker, E., & Borsello, T. (2014) · Cell Death and Disease · doi:10.1038/cddis.2013.559 · Cited by 103 · see citing works

Sex and estrogens alter the action of glucagon-like peptide-1 on reward

Richard, J. E., Anderberg, R. H., López-Ferreras, L., Olandersson, K., & Skibicka, K. P. (2016) · Biology of Sex Differences · doi:10.1186/s13293-016-0059-9 · Cited by 102 · see citing works

Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer’s disease

Zheng, M., & Wang, P. (2021) · 3 Biotech · doi:10.1007/s13205-021-02738-3 · Cited by 98 · see citing works

Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic Mice

Chen, S., Sun, J., Zhao, G., Guo, A. W., Chen, Y., Fu, R., & Deng, Y. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2250-8 · Cited by 95 · see citing works

Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline

Gourmaud, S., Paquet, C., Dumurgier, J., Pace, C., Bouras, C., Gray, F., Laplanche, J., MEURS, E. F., Mouton‐Liger, F., & Hugon, J. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140062 · Cited by 95 · see citing works

Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies

Mistur, R. L., Mosconi, L., Santi, S. D., Guzman, M., Li, Y., Tsui, W., & de Leon, M. J. (2009) · Journal of Clinical Neurology · doi:10.3988/jcn.2009.5.4.153 · Cited by 94 · see citing works

The Neuroprotection of Liraglutide on Alzheimer-Like Learning and Memory Impairment by Modulating the Hyperphosphorylation of Tau and Neurofilament Proteins and Insulin Signaling Pathways in Mice

Xiong, H., Chen, Z., Wang, J., Song, J., Zhao, G., Shen, H., & Deng, Y. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130584 · Cited by 90 · see citing works

Perspectives in GLP-1 Research: New Targets, New Receptors

Cantini, G., Mannucci, E., & Luconi, M. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.03.017 · Cited by 89 · see citing works

Neurotrophic Property of Geniposide for Inducing the Neuronal Differentiation of PC12 Cells

Liu, J., Zheng, X., Yin, F., Hu, Y., Guo, L., Deng, X., Chen, G., Jiajia, J., & Zhang, H. (2006) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2006.08.009 · Cited by 86 · see citing works

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases

Cheng, D., Yang, S., Zhao, X., & Wang, G. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s348055 · Cited by 84 · see citing works

Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists

Finan, B., Clemmensen, C., & Müller, T. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.003 · Cited by 81 · see citing works

Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial.

Egefjord, L., Gejl, M., Møller, A., Brændgaard, H., Gottrup, H., Antropova, O., Møller, N., Poulsen, H. E., GJEDDE, A. H., Brock, B., et al. (2012) · PubMed · Cited by 80 · see citing works

Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5×FAD mouse model of Alzheimer’s disease

An, J., Zhou, Y., Zhang, M., Xie, Y., Ke, S., Liu, L., Pan, X., & Zhou, C. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.111932 · Cited by 79 · see citing works

LDLR-related protein 10 (LRP10) regulates amyloid precursor protein (APP) trafficking and processing: evidence for a role in Alzheimer’s disease

Brodeur, J., Thériault, C., Lessard-Beaudoin, M., Marcil, A., Dahan, S., & Lavoie, C. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-31 · Cited by 77 · see citing works

Exendin-4 attenuates brain mitochondrial toxicity through PI3K/Akt-dependent pathway in amyloid beta (1–42)-induced cognitive deficit rats

Garabadu, D., & Verma, J. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.04.006 · Cited by 75 · see citing works

ICV STZ induced impairment in memory and neuronal mitochondrial function: A protective role of nicotinic receptor

Saxena, G., Patro, I. K., & Nath, C. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.04.039 · Cited by 73 · see citing works

GLP-1 receptor agonists downregulate aberrant GnT-III expression in Alzheimer's disease models through the Akt/GSK-3β/β-catenin signaling

Wang, Y., Chen, S., Zheng, X., Chen, S., Yao, W., & Gao, X. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.048 · Cited by 67 · see citing works

Resveratrol in experimental Alzheimer’s disease models: A systematic review of preclinical studies

Chen, J.-Y., Zhu, Q., Zhang, S., Ouyang, D., & Lu, J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104476 · Cited by 67 · see citing works

Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease

Bomba, M., Granzotto, A., Castelli, V., ONOFRJ, M. C., Lattanzio, R., Cimini, A., & Sensi, S. L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-190237 · Cited by 64 · see citing works

Estradiol Binds to Insulin and Insulin Receptor Decreasing Insulin Binding in vitro

Root-Bernstein, R. S., Podufaly, A., & Dillon, P. F. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00118 · Cited by 63 · see citing works

Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease

Hansen, H. H., Fabricius, K., Barkholt, P., Wismann, P., Schlumberger, C., Jelsing, J., Terwel, D., Termont, A., Pyke, C., Knudsen, L. B., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158205 · Cited by 63 · see citing works

Liraglutide Suppresses Tau Hyperphosphorylation, Amyloid Beta Accumulation through Regulating Neuronal Insulin Signaling and BACE-1 Activity

Jantrapirom, S., Nimlamool, W., Chattipakorn, N., Chattipakorn, S. C., Temviriyanukul, P., Inthachat, W., Govitrapong, P., & Potikanond, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051725 · Cited by 63 · see citing works

Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives

Ferrari, F., Moretti, A., & Villa, R. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108277 · Cited by 61 · see citing works

Evidence for altered insulin receptor signaling in Alzheimer's disease

Griffith, C. M., Eid, T., Rose, G. M., & Patrylo, P. R. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.008 · Cited by 61 · see citing works

Glucagon-like peptide-1 analogs mitigate neuroinflammation in Alzheimer's disease by suppressing NLRP2 activation in astrocytes

Zhang, M., Wu, Y., Gao, R., Chen, X., Chen, R., & Zhou, C. Y. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111529 · Cited by 60 · see citing works

Casein kinase-1 isoforms differentially associate with neurofibrillary and granulovacuolar degeneration lesions

Kannanayakal, T. J., Tao, H., Vandré, D. D., & Kuret, J. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0049-9 · Cited by 59 · see citing works

Prevention of Cognitive Decline in Alzheimer’s Disease by Novel Antioxidative Supplements

Tadokoro, K., Ohta, Y., Inufusa, H., Loon, A. F. N., & Abe, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061974 · Cited by 58 · see citing works

Neuronal polo-like kinase in Alzheimer disease indicates cell cycle changes

Harris, P. L. R. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00218-9 · Cited by 56 · see citing works

Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro

An, F.-M., Chen, S., Xu, Z., Yin, L., Wang, Y., Liu, A.-R., Yao, W.-B., & Gao, X.-D. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.023 · Cited by 55 · see citing works

Combined Donepezil with Astaxanthin via Nanostructured Lipid Carriers Effective Delivery to Brain for Alzheimer’s Disease in Rat Model

Shehata, M. K., Ismail, A. A., & Kamel, M. A. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s417928 · Cited by 55 · see citing works

Metabolic regulation by secreted phospholipase A2

Sato, H., Taketomi, Y., & Murakami, M. (2016) · Inflammation and Regeneration · doi:10.1186/s41232-016-0012-7 · Cited by 54 · see citing works

NLRP2 inflammasome in dorsal root ganglion as a novel molecular platform that produces inflammatory pain hypersensitivity

Matsuoka, Y., Yamashita, A., Matsuda, M., Kawai, K., Sawa, T., & Amaya, F. (2019) · Pain · doi:10.1097/j.pain.0000000000001611 · Cited by 50 · see citing works

Sex specific molecular networks and key drivers of Alzheimer’s disease

Guo, L., Cao, J., Hou, J., Li, Y., Huang, M., Zhu, L., Zhang, L., Lee, Y., Duarte, M. L., Zhou, X., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00624-5 · Cited by 49 · cited 3× · see citing works

Novel Glucagon-Like Peptide-1 (GLP-1) Analog (Val8)GLP-1 Results in Significant Improvements of Glucose Tolerance and Pancreatic β-Cell Function after 3-Week Daily Administration in Obese Diabetic (ob/ob) Mice

Green, B. D., Lavery, K. S., Irwin, N., O’Harte, F. P. M., Harriott, P., Greer, B., Bailey, C. J., & Flatt, P. R. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097824 · Cited by 49 · see citing works

Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus

Pelle, M. C., Zaffina, I., Giofrè, F., Pujia, R., & Arturi, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411301 · Cited by 49 · see citing works

The role of genetic risk factors of Alzheimer’s disease in synaptic dysfunction

Fu, W.-Y., & Ip, N. Y. (2023) · Seminars in Cell &amp; Developmental Biology · doi:10.1016/j.semcdb.2022.07.011 · Cited by 48 · see citing works

Restoration of Cerebral and Systemic Microvascular Architecture in APP / PS 1 Transgenic Mice Following Treatment with Liraglutide™

Kelly, P., McClean, P. L., Ackermann, M., Konerding, M. A., Hölscher, C., & Mitchell, C. A. (2014) · Microcirculation · doi:10.1111/micc.12186 · Cited by 47 · see citing works

Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon‐like peptide‐1 receptor agonists

Yassine, H. N., Solomon, V. A., Thakral, A., Sheikh‐Bahaei, N., Chui, H. C., Braskie, M. N., Schneider, L. S. S., & Talbot, K. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12474 · Cited by 42 · see citing works

Screening with an NMNAT2-MSD platform identifies small molecules that modulate NMNAT2 levels in cortical neurons

Ali, Y., Bradley, G., & Lu, H. (2017) · Scientific Reports · doi:10.1038/srep43846 · Cited by 42 · see citing works

A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer’s Disease

Lynn, J., Park, M., Ogunwale, C., & Acquaah-Mensah, G. K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210612 · Cited by 42 · see citing works

Stimulation of glycolytic key enzymes in cerebral cortex by insulin

Hoyer, S., Prem, L., Sorbi, S., & Amaducci, L. A. (1993) · Neuroreport · doi:10.1097/00001756-199307000-00039 · Cited by 41 · see citing works

The Protein Phosphatase Inhibitor Okadaic Acid Induces Heat Shock Protein Expression and Neurodegeneration in Rat Hippocampusin Vivo

Arias, C., Becerra-Garcı́a, F., Arrieta, I., & Tapia, R. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6900 · Cited by 40 · see citing works

BACE inhibitor reduces APP-β-C-terminal fragment accumulation in axonal swellings of okadaic acid-induced neurodegeneration

Yoon, S. Y., Choi, J. E., Yoon, J. H., Huh, J., & Kim, D. H. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.013 · Cited by 39 · see citing works

Combination of Insulin with a GLP1 Agonist Is Associated with Better Memory and Normal Expression of Insulin Receptor Pathway Genes in a Mouse Model of Alzheimer’s Disease

Robinson, A., Lubitz, I., Atrakchi, D., Licht-Murava, A., Katsel, P., LeRoith, D., Zaltsman, S. L., Haroutunian, V. H., & Beeri, M. S. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-1257-9 · Cited by 37 · see citing works

Exendin-4, a glucagon-like peptide 1 receptor agonist, protects against amyloid-β peptide-induced impairment of spatial learning and memory in rats

Jia, X.-T., Ye-Tian, Yuanli, Zhang, G., Liu, Z., Di, Z., Ying, X., Yan, F., Song, E., Qi, J., et al. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.03.016 · Cited by 36 · see citing works

In vivo network models identify sex differences in the spread of tau pathology across the brain

Shokouhi, S., Taylor, W. D., Albert, K., Kang, H., Newhouse, P. A., & Initiative, T. A. D. N. (2020) · Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring · doi:10.1002/dad2.12016 · Cited by 35 · see citing works

Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus

Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., & Mallo, F. (2022) · Vitamins and hormones · doi:10.1016/bs.vh.2021.12.005 · Cited by 33 · see citing works

Exendin-4 antagonizes Aβ1-42-induced attenuation of spatial learning and memory ability

Wang, X., Wang, L., Jiang, R., Xu, Y., Zhao, X., & Li, Y. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3742 · Cited by 33 · see citing works

TREM2 and Microglia Contribute to the Synaptic Plasticity: from Physiology to Pathology

Yu, C.-J., Wang, M., Ruiyang, L., Wei, T., Yang, H.-C., Yin, Y., Mi, Y., Qin, Q., & Tang, Y. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03100-1 · Cited by 33 · see citing works

Intranasal administration of Exendin-4 antagonizes Aβ31–35-induced disruption of circadian rhythm and impairment of learning and memory

Wang, X., Wang, L., Xu, Y., Yu, Q., Li, L., & Guo, Y. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-016-0548-z · Cited by 31 · see citing works

The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist

Bain, S. C. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0073-z · Cited by 29 · see citing works

(Val8)GLP‐1‐Glu‐PAL: a GLP‐1 Agonist That Improves Hippocampal Neurogenesis, Glucose Homeostasis, and β‐Cell Function in High‐Fat‐Fed Mice

Lennox, R., Porter, D. W., Flatt, P. R., & Gault, V. A. (2012) · ChemMedChem · doi:10.1002/cmdc.201200409 · Cited by 28 · see citing works

Cognitive Effects of MDMA in Laboratory Animals: A Systematic Review Focusing on Dose

Pantoni, M. M., & Anagnostaras, S. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017087 · Cited by 25 · see citing works

miR-503/Apelin-12 mediates high glucose-induced microvascular endothelial cells injury via JNK and p38MAPK signaling pathway

Chen, K., Zhao, X.-L., Li, L.-B., Huang, L., Tang, Z., Luo, J., Yang, L., Qin, A.-P., & Hu, F. (2020) · Regenerative Therapy · doi:10.1016/j.reth.2019.12.002 · Cited by 25 · see citing works

The role of GLP-1/GIP receptor agonists in Alzheimer’s disease

Yu, C. J., Song, L. L., Zhai, Z. N., Tao, Y., Zhang, Y., Cai, L. Y., Hou, Y. H., Chen, H. Y., & Wang, L. (2020) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/121007 · Cited by 23 · see citing works

Downregulation of the GLP-1/CREB/adiponectin pathway is partially responsible for diabetes-induced dysregulated vascular tone and VSMC dysfunction

Xiong, X., Lu, W., Qin, X., Luo, Q., & Zhou, W. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110218 · Cited by 22 · see citing works

Expansion of the Golgi apparatus in rat cerebral cortex following intracerebroventricular injections

Grieb, P., Kryczka, T., Fiedorowicz, M., Frontczak‐Baniewicz, M., & Walski, M. (2004) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2004-1531 · Cited by 17 · see citing works

Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases

Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193 · see citing works

Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis

Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116 · see citing works

The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice

Forny Germano, L., Koehler, J. A., Baggio, L. L., Cui, F., Wong, C. K., Rittig, N., Cao, X., Matthews, D., & Drucker, D. J. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102019 · Cited by 50 · see citing works

Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity

Lin, H.-T., Tsai, Y.-F., Liao, P.-L., & Wei, J. C.-C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.21016 · Cited by 43 · see citing works

Comprehensive Evaluation of GLP-1 Receptor Agonists: An Umbrella Review of Clinical Outcomes across Multiple Diseases

Kong, F., Zhao, Y., Zhang, W., Wang, X., Wu, T., Zhou, Z., Xu, Y., Xia, L., & Sun, T. (2026) · Nature Communications · doi:10.1038/s41467-025-67701-9 · Cited by 29 · see citing works

The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype

Noguchi, T., Katoh, H., Nomura, S., Okada, K., & Watanabe, M. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1342944 · Cited by 20 · see citing works